Sentence examples for in time to development from inspiring English sources

Kaplan-Meier analysis did not reveal significant differences in time to development of IA between recipients or their donors bearing either only the wild-type or variant allele.

At all doses tested, subtle but statistically significant delays in time to development of external lesions were noted in groups of mice inoculated with HSV-2/gD-Q27P compared with HSV-2/gD.

Peripheral neuropathy was reported equally in both genders (approximately 17%), with no difference in time to development between the drug groups.

We also performed the log-rank test, Kaplan Meier analysis, and Fine Gray competing risk analysis to determine the differences in time to development of bone metastasis and time to death between the two groups.

Also, between the combined treatment eras 'noCTx'/'5-FU' and the era 'contempCTx', there was no significant difference in terms of median tumour-related survival (synPC and metaPC: 20.0 months vs 26.4 months, P=0.33) nor in time to development of PC (metaPC: 17.9 months vs 22.1 months, P=0.19).

While basal-like breast cancer has the worst clinical outcome measured in time to development of distant metastasis [ 8], there is still some controversy on the histologic classification of this subtype regarding whether triple negative status is required for making the diagnosis of basal-like carcinoma.

There were 5.1% (p = 0.01) and 12.1% (p less than or equal to 0.0001) decreases in the time to development of ischemic ST-segment changes after exposures producing 2.0 and 3.9% COHb, respectively, compared to the control day.

Using data from only two sequential annual photographic screening visits supported by a quality-controlled grading system, we documented significant differences in the time to development of retinopathy requiring referral to an ophthalmologist.

The time frame of treatment and diagnosis for this audit should provide sufficient follow-up to allow for the development of any late complications, and there does seem to be a difference in the time to development of late complications between the treatment groups.

This avoided the error of giving the aspirin users "immortal" person-time (i.e. the error in overestimating the time to development of endpoint if the index date taken was earlier than the time when aspirin was initiated) [ 12].

In an analysis of time to development of severe disease in diffuse SSc, a large group of more than 400 patients from the Pittsburgh Scleroderma Databank was assessed over 10 years.